Better Health for All

Agenus Inc. is entirely focused on developing immunotherapies for cancer and infectious diseases, with 100% of its product portfolio and R&D investment dedicated to this area. The company markets the Oncophage vaccine for kidney cancer

and has the BOT/BAL combination in Phase 3 clinical development . This combination has demonstrated durable survival in over 1,200 patients across nine metastatic, late-line cancers , achieving 42% two-year overall survival and 20.9-month median overall survival in heavily pretreated MSS mCRC patients . Agenus provides access to investigational medicines through France's reimbursed compassionate access (AAC) program , offering fully reimbursed treatment for specific adult French patients with difficult-to-treat cancers . Paid access programs are also available in several European countries and other regions .

Fair Money & Economic Opportunity

Agenus Inc. is a clinical-stage immuno-oncology company focused on developing cancer therapies, not a financial institution. The company does not offer lending, deposit, or other consumer financial services. Therefore, all Key Performance Indicators related to fair money and economic opportunity, which are designed for financial service providers, are not applicable. The company's financial activities, such as corporate promissory notes with an 8% annual interest rate

and 13.5% compounded quarterly, relate to its own financing and not to providing financial products to consumers. Mentions of 'underserved populations' refer to patients with specific medical conditions, not financially underserved clients.

Fair Pay & Worker Respect

For Fiscal Year 2024, Agenus Inc. reported a CEO to median employee pay ratio of 32:1

, with the CEO's total compensation at $3,717,621 and median employee pay at $114,901 . Employee feedback indicates low engagement, with an overall employee rating of 2.8 out of 5 stars on Indeed and 2.9 out of 5 stars on Glassdoor . Only 40% of employees would recommend working at Agenus to a friend , 29% approve of the CEO , and 19% view the business outlook positively . The company's Code of Business Conduct and Ethics commits to maintaining a safe and healthy work environment , prohibits violence and discrimination , and provides an anonymous reporting line for violations . There is no public record of substantiated labor-law or human-rights violations in the past three years. However, employee reviews describe a "very toxic" work culture , "highest turnover" , and "at least 4 strings of layoffs" in one department over nine months , including a 25% workforce reduction . Benefits mentioned positively include health insurance with "many choices" and "good medical coverage" , a 401K plan with a 3% company match , unlimited PTO , maternity/paternity leave , and an employee stock purchase plan .

Fair Trade & Ethical Sourcing

The provided articles do not contain any information regarding Agenus Inc.'s fair trade certifications, supplier audit frequency, forced or child labor incidents in its supply chain, traceability coverage, remediation speed for violations, ethical clauses in supplier contracts, materials risk index, or supplier diversity spend.

The Code of Business Conduct and Ethics outlines internal ethical guidelines for the company's employees, officers, and directors, but does not detail supplier-specific ethical sourcing practices or the inclusion of ethical clauses in supplier contracts.

Honest & Fair Business

A securities class action lawsuit was filed against Agenus Inc., alleging that the company issued materially false and/or misleading statements regarding the effectiveness of its immuno-oncology products and overstated clinical results, regulatory, and commercial prospects between January 23, 2023, and July 17, 2024.

The deadline for shareholders to register for the class action is November 5, 2024. The company has not reported any regulatory fines, violations, or compliance issues in the past three years. The financial statement period in the 10-K filing up to December 31, 2024, does not include a restatement due to error correction. A compensation recoupment policy, effective June 9, 2023, is in place for executive compensation if an accounting restatement is required due to material errors or noncompliance, with a three-year lookback period. Agenus has a comprehensive whistleblower policy, revised in January 2024, which includes an anonymous reporting line, a dedicated ethics website, email, and mail to the Lead Director. This policy explicitly states protection against retaliation for good faith reporting and applies globally to all directors, officers, employees, and consultants, with the exception of MiNK Therapeutics, Inc. The company also has a General Anti-Bribery Policy and a Global Anti-Corruption Policy, located on its Intranet, which strictly prohibits bribes, kickbacks, and other improper payments, gifts, or benefits. The Global Anti-Corruption Policy provides detailed guidance on the FCPA and related anti-bribery laws and regulations and applies globally to Agenus Inc. and its subsidiaries, with the exception of MiNK Therapeutics, Inc.

Kind to Animals

Agenus is committed to respecting animal welfare in its research activities

and expects employees to be familiar with policies and procedures ensuring compliance with applicable laws and regulations . Managers are responsible for training employees on these policies , which were revised in January 2024 . However, the available information does not detail specific prohibitions on non-essential testing, measurable reduction goals, or external oversight, indicating a vague policy.

No War, No Weapons

Agenus Inc. is an immuno-oncology company focused on discovering and developing therapies to fight cancer. There is no evidence of the company deriving revenue from arms or defense contracts, nor any involvement in dual-use technologies with military applications.

Its AI systems are explicitly used for civilian medical purposes, specifically for biomarker discovery and precision medicine in oncology, aligning with FDA priorities. No evidence indicates exposure to controversial or banned weapons, or any defense-related assets requiring divestment. The company's Code of Business Conduct and Ethics outlines general ethical and legal obligations, with board committees providing oversight on compliance and ethics, but there is no specific mention of policies or activities related to war or weapons.

Planet-Friendly Business

Agenus reported total Scope 1, 2, and 3 emissions of 1,446 tCO₂e in 2023.

The company has achieved Carbon Neutral status for the second consecutive year. At its Newton Abbot, Lancing, and Stafford sites, 0% of waste was sent to landfill, with all waste recycled, incinerated for energy, or processed into RDF/SRF. The company maintains ISO 14001 certification and has no reported environmental compliance violations. There is no mention of SBTi-validated science-based targets or TCFD climate-risk disclosures. The company has developed a responsible purchasing policy and supplier charter, with a percentage of existing suppliers undergoing due diligence checks. Environmental volunteering efforts included removing 284kg of waste from local parks and waterways.

Respect for Cultures & Communities

Agenus states that improving the social, economic, and environmental wellbeing of the community where it does business is a high priority

, and it respects internationally recognized human rights throughout its operations . The company promotes Diversity, Equality, and Inclusion (DEI) and provides training and development opportunities . An ESG Committee exists and meets at least quarterly , and materiality assessments are performed periodically to determine expectations of internal and external stakeholders . The company also complies with national and international standards and regulations pertaining to environmental and social needs . Additionally, Agenus monitors channels and may take actions such as blocking users or reporting posts to law enforcement to protect public safety . However, the provided information does not include specific data on formal partnerships with indigenous or local community groups, the percentage of revenue reinvested in local community development, any cultural appropriation incidents, or the existence of a formal cultural impact assessment protocol. There is also no data on local employment ratios, the availability of community-specific grievance mechanisms, the average time to resolve community complaints, FPIC participation rates, community representation in governance, investment in cultural preservation, local procurement share, indigenous supplier counts, cultural site protection, social license to operate, charitable giving to cultural heritage organizations, community fund allocation, language inclusivity, or cultural sensitivity training completion.

Safe & Smart Tech

Agenus Inc.'s privacy policy states compliance with applicable laws, including GDPR and CCPA.

It outlines that users can request access, rectification, erasure, restriction, and data portability of their personal data. Data retention is for the time necessary to provide services, meet legal obligations, or for business needs. The provided documents do not contain information regarding data breaches, AI ethics, cybersecurity investment, privacy certifications, security training, encryption, AI audits, algorithmic transparency, unauthorized data use, authentication security, vulnerability management, bug bounty programs, privacy by design, security testing, algorithmic harm remediation, or digital rights advocacy.

Zero Waste & Sustainable Products

Agenus is developing a novel plant cell-culture based method for QS-21 production, funded by a ~$1M grant from the Bill & Melinda Gates Foundation

. This "environment friendly manufacturing technique" will serve as an alternative to sourcing QS-21 from Chilean soap bark trees . The company focuses on the elimination of waste and pollution, recycling where possible, and minimizing the use of plastic . Agenus ensures wastewater effluents are discharged appropriately . An ESG Committee has been established to articulate and frame targets for environmental stewardship and sustainability , but specific waste reduction targets are not yet defined.